Nicholas Bacopoulos
Director/Board Member at MAKScientific LLC
Profile
Nicholas G.
Bacopoulos is the founder of Medexis Biotech SA. He is currently the Director at MAKScientific LLC.
Previously, he served as the President & Chief Executive Officer at Mersana Therapeutics, Inc. and Aton Pharma, Inc. He was also the President & Chief Executive Officer at Anaderm Research Corp.
He served as an Independent Director at Cyclacel Pharmaceuticals, Inc. from 2008 to 2016.
He was a Director at Priaxon AG and Kotinos Pharmaceuticals, Inc. He served as the President & Head-Research & Development at OSI Pharmaceuticals, Inc. and as a Principal at Pfizer Central Research.
He was a Faculty Member at Dartmouth Medical School.
He completed his undergraduate degree at Cornell College (Iowa) and his doctorate at the University of Iowa.
Nicholas Bacopoulos active positions
| Companies | Position | Start |
|---|---|---|
MAKScientific LLC
 MAKScientific LLC Pharmaceuticals: MajorHealth Technology MAKScientific LLC develops drugs to treat medical disorders by modulating the endocannabinoid system. The firm discovers medications for metabolic disorders, pain, addiction, and neurological diseases. The company was founded by Alexandros Makriyannis in 2004 and is headquartered in Mystic, CT. | Director/Board Member | - |
Former positions of Nicholas Bacopoulos
| Companies | Position | End |
|---|---|---|
| CYCLACEL PHARMACEUTICALS, INC. | Director/Board Member | 2016-06-30 |
Priaxon AG
 Priaxon AG Miscellaneous Commercial ServicesCommercial Services Priaxon AG operates as a drug discovery company for small molecule therapeutics. The firm develops a platform PriaXplore that consists of several chemo informatics methods and concepts especially designed for the application in the field of identifying new potential inhibitors of protein protein interactions (PPI). The company was founded by Christoph Burdack in 2008 and is headquartered in Munich, Germany. | Director/Board Member | - |
| Dartmouth Medical School | Corporate Officer/Principal | - |
| Anaderm Research Corp. | Chief Executive Officer | - |
| Pfizer Central Research | Corporate Officer/Principal | - |
Training of Nicholas Bacopoulos
| Cornell College (Iowa) | Undergraduate Degree |
| University of Iowa | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| MERSANA THERAPEUTICS, INC. | Health Technology |
| CYCLACEL PHARMACEUTICALS, INC. | Health Technology |
| Private companies | 8 |
|---|---|
OSI Pharmaceuticals, Inc.
 OSI Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OSI Pharmaceuticals, Inc. manufactured and develope dpharmaceutical drugs. The company was founded in 1983 and was headquartered in Farmingdale, NY. | Health Technology |
Aton Pharma, Inc.
 Aton Pharma, Inc. Pharmaceuticals: MajorHealth Technology Aton Pharma, Inc. develops therapeutics for cancer and other diseases. Its products include Edecrin, Sodium Edecrin, Cuprimine, Demser and Syprine. The company was founded by Michael G. Wells in 2001 and is headquartered in Lawrenceville, NJ. | Health Technology |
| Pfizer Central Research | |
| Medexis Biotech SA | |
MAKScientific LLC
MAKScientific LLC Pharmaceuticals: MajorHealth Technology MAKScientific LLC develops drugs to treat medical disorders by modulating the endocannabinoid system. The firm discovers medications for metabolic disorders, pain, addiction, and neurological diseases. The company was founded by Alexandros Makriyannis in 2004 and is headquartered in Mystic, CT. | Health Technology |
| Kotinos Pharmaceuticals, Inc. | |
| Anaderm Research Corp. | |
Priaxon AG
Priaxon AG Miscellaneous Commercial ServicesCommercial Services Priaxon AG operates as a drug discovery company for small molecule therapeutics. The firm develops a platform PriaXplore that consists of several chemo informatics methods and concepts especially designed for the application in the field of identifying new potential inhibitors of protein protein interactions (PPI). The company was founded by Christoph Burdack in 2008 and is headquartered in Munich, Germany. | Commercial Services |
- Stock Market
- Insiders
- Nicholas Bacopoulos
